Skip to main content
SpringerLink
Log in
Book cover

Radiation Oncology pp 429–443Cite as

Multiple Myeloma and Plasmacytoma

  • Chapter

  • 1966 Accesses

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

Abstract

Multiple myeloma is a malignancy of post-germinal center B-cells characterized by accumulation of abnormal clonal plasma cell secreting monoclonal proteins in the bone marrow. In many instances, it is preceded by monoclonal gammopathy of undetermined significance (MGUS), a pre-malignant stage that is present in approximately 3% of individuals above 50, or a more advanced stage of clonal expansion where the patient is still asymptomatic, called smoldering myeloma.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adamietz IA, Schöber C, Schulte RW, et al (1991) Palliative radiotherapy in plasma cell myeloma. Radiother Oncol 20:111–116

    Article  PubMed  CAS  Google Scholar 

  • Alexiou C, Kau RJ, Dietzfelbinger H, et al (1999) Extramedullary plasmacytoma: Tumor occurrence and therapeutic concepts. Cancer 85:2305–2314

    Article  PubMed  CAS  Google Scholar 

  • Avilés A, Huerta-Guzmán J, Delgado S, et al (1996) Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol 14:111–117

    Article  PubMed  Google Scholar 

  • Attal M, Harousseau JL, Stoppa JM, et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. New Engl J Med 335:91–97

    Article  PubMed  CAS  Google Scholar 

  • Attal M, Harousseau JL, Facon T, et al (2006a) Single versus double autologous stem-cell transplantation for multiple myeloma. New Engl J Med 349:2495–2502

    Article  Google Scholar 

  • Attal M, Harousseau JL, Leyvraz S, et al. (2006b) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108(10): 3289–3294

    Article  PubMed  CAS  Google Scholar 

  • Avet-Loisseau H, Attal M, Moreau P, et al (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109:3489–3495

    Article  CAS  Google Scholar 

  • Badros A, Barlogie B, Morris C, et al (2001) Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 114:822–829

    Article  PubMed  CAS  Google Scholar 

  • Barlogie B, Kyle RA, Anderson KC, et al (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24:929–936

    Article  PubMed  CAS  Google Scholar 

  • Bennett CL, Angelotta C, Yarnold PR, et al (2006) Thalidomide-and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296:2558–2560

    Article  PubMed  CAS  Google Scholar 

  • Blade J, Rosinol L, Sureda A, et al (2005) High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a pro-spective randomized trial from the Spanish cooperative group PETHEMA. Blood 106:3755–3759

    Article  PubMed  CAS  Google Scholar 

  • Bosch A, Frias Z (1988) Radiotherapy in the treatment of multiple myeloma. Int J Radiat Oncol Biol Phys 15:1363–1369

    PubMed  CAS  Google Scholar 

  • Bourhis JH, Bouko Y, Koscielny S, et al (2007) Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long-term follow-up of an EBMT phase III randomized study. Hematologica 92:1083–1090

    Article  Google Scholar 

  • Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. (2003) Serum testing for assessing patients with Bence Jones myeloma. Lancet 361(9356):489–491

    Article  PubMed  Google Scholar 

  • Bruno B, Rotta M, Patriarca F, et al (2007) A comparison of allografting with autografting for newly diagnosed myeloma. New Engl J Med 356:1110–1120

    Article  PubMed  CAS  Google Scholar 

  • Catell D, Kogen Z, Donahue B, et al (1998) Multiple myeloma of an extremity: must the entire bone be treated? Int J Radiat Oncol Biol Phys 40:117–119

    Article  PubMed  CAS  Google Scholar 

  • Cavo M, Zamagni E, Tosi P, et al (2005) Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106:35–39

    Article  PubMed  CAS  Google Scholar 

  • Cavo M, Tosi P, Zamagni E, et al (2007) Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 25:2434–2341

    Article  PubMed  Google Scholar 

  • Child JA, Morgan GJ, Davies FE, et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New Engl J Med 348:1875–1883

    Article  PubMed  CAS  Google Scholar 

  • Chng WJ, Ahmann GJ, Henderson K, et al (2006) Clinical implication of centrosome amplification in plasma cell neoplasm. Blood 107:3669–3675

    Article  PubMed  CAS  Google Scholar 

  • Chng WJ, Price-Troska T, Gonzalez-Paz N, et al (2007) Clinical significance of TP53 mutation in myeloma. Leukaemia 21:582–584

    Article  CAS  Google Scholar 

  • Clark WF, Stewart AK, Rock GA, et al (2005) Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 143:777–784

    PubMed  Google Scholar 

  • Corradini P, Cavo M, Lokhorst M, et al (2003) Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 102:1927–1929

    Article  PubMed  CAS  Google Scholar 

  • Dimopoulos M, Spencer A, Attal M, et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New Engl J Med 357:2123–2132

    Article  PubMed  CAS  Google Scholar 

  • Djulbegovic B, Wheatley K, Ross J, et al (2002) Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev CD003188

    Google Scholar 

  • Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR (2001) Serum free light chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97:2900–2902

    Article  PubMed  CAS  Google Scholar 

  • Durie BGM, Harousseau JL, Miguel JS, et al (2006). International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473

    Article  PubMed  CAS  Google Scholar 

  • Facon T, Mary JY, Pergourie B, et al (2006) Dexamethasonebased regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107:1292–1298

    Article  PubMed  CAS  Google Scholar 

  • Facon T, Mary JY, Hulin C, et al (2007). Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370(9594):1209–1218

    Article  PubMed  CAS  Google Scholar 

  • Featherstone C, Delaney G, Jacob S, et al (2005) Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II-leukemia and myeloma. Cancer 103:393–401

    Article  PubMed  Google Scholar 

  • Fermand JP, Ravaud P, Chevret S, et al (1998) High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92:3131–3136

    PubMed  CAS  Google Scholar 

  • Fermand JP, Katsahian S, Divine M, et al (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23:9227–9233

    Article  PubMed  CAS  Google Scholar 

  • Fonseca R, Barlogie B, Bataille R, et al (2004). Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64:1546–1558

    Article  PubMed  CAS  Google Scholar 

  • Garban F, Attal M, Michallet M, et al (2006) Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107:3474–3480

    Article  PubMed  CAS  Google Scholar 

  • Gertz MA, Lacy M. Dispenzieri A, et al (2005) Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy. Blood 106:2837–2840

    Article  PubMed  CAS  Google Scholar 

  • Ghanem N, Lohrmann C, Engelhardt M, et al (2006) Wholebody MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol 16:1005–1014

    Article  PubMed  Google Scholar 

  • Glasmacher A, Hahn C, Hoffmann F, et al (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132:584–593

    Article  PubMed  CAS  Google Scholar 

  • Greipp PR, Lust JA, O’Fallon WM, Katzmann JA, Witzig TE, Kyle RA (1993) Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81:3382–3387

    PubMed  CAS  Google Scholar 

  • Greipp PR, Leong T, Bennett JM, et al (1998) Plasmablastic morphology-an independent prognostic factor with clinical and laboratory correlate: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG myeloma laboratory group. Blood 91:2501–2507

    PubMed  CAS  Google Scholar 

  • Greipp PR, San Miguel J, Durie BG, et al (2005). International staging system for multiple myeloma. J Clin Oncol 23:3412–3420

    Article  PubMed  Google Scholar 

  • Hernandez JM, Garcia-Sanz R, Golvano E, et al (2004) Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 127:159–164

    Article  PubMed  CAS  Google Scholar 

  • Hjorth M, Hellquist L, Holmberg E et al (1993) Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I — a randomized study. Myeloma Group of Western Sweden. Eur J Haematol 50:95–102

    Article  PubMed  CAS  Google Scholar 

  • Jacobson JL, Hussain MA, Barlogie B, et al (2003) A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 122:441–450

    Article  PubMed  Google Scholar 

  • Jantunen E, Kuittinen T, Penttila K, Lehtonen P, Mahlamaki E, Nousiainen T (2006) High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (≥65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transpant 37:917–922

    Article  CAS  Google Scholar 

  • Johnson WJ, Kyle RA, Pineda AA, O’Brien PC, Holley KE (1990) Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 150:863–869

    Article  PubMed  CAS  Google Scholar 

  • Knobel D, Zouhair A, Tsang RW, et al (2006) Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer 6:118

    Article  PubMed  Google Scholar 

  • Knudsen LM, Nielsen B, Gimsing P, Geisler C (2005) Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 75:27–33

    Article  PubMed  Google Scholar 

  • Kumar S, Lacy MQ, Dispenzieri A, et al (2004) Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 34:485–490

    Article  PubMed  CAS  Google Scholar 

  • Kyle RA, Yee GC, Somerfield MR, et al (2007) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25:2464–2472

    Article  PubMed  CAS  Google Scholar 

  • Lee CK, Zangari M, Barlogie B, et al (2004) Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 33:823–828

    Article  PubMed  CAS  Google Scholar 

  • Leigh BR, Kurtts TA, Mack CF, et al (1993) Radiation therapy for the palliation of multiple myeloma. Int J Radiat Oncol Biol Phys 25:801–804

    PubMed  CAS  Google Scholar 

  • Mendenhall CM, Thar TL, Million RR (1980) Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys 6:1497–1501

    PubMed  CAS  Google Scholar 

  • Mill WB, Griffith R (1980) The role of radiation therapy in the management of plasma cell tumors. Cancer 45:647–652

    Article  PubMed  CAS  Google Scholar 

  • Moreau P, Facon T, Attal M, et al (2002) Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 99:731–735

    Article  PubMed  CAS  Google Scholar 

  • Moulopoulos LA, Dimopoulos MA, Weber D, et al (1993) Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 11:1311–1315

    PubMed  CAS  Google Scholar 

  • Myeloma Trialists’ Collaborative Group (2001) Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113:1020–1034

    Article  Google Scholar 

  • Orlowski RZ, Nagler A, Sonneveld P, et al (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25:3892–3901

    Article  PubMed  CAS  Google Scholar 

  • Ozsahin M, Tsang RW, Poortmans P, et al (2006) Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys 64:210–217

    PubMed  Google Scholar 

  • Palumbo A, Bringhen S, Caravita T, et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367(9513):825–831

    Article  PubMed  CAS  Google Scholar 

  • Rades D, Hoskin PJ, Stalpers LJ, et al (2006) Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. Int J Radiat Oncol Biol Phys 64:1452–1457

    PubMed  Google Scholar 

  • Rajkumar SV, Blood E, Vesole D, et al (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431–436

    Article  PubMed  CAS  Google Scholar 

  • Reece DE, Bredeson C, Perez WS, et al (2003) Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age. Bone Marrow Transplant 32:1135–1143

    Article  PubMed  CAS  Google Scholar 

  • Riccardi A, Mora O, Tinelli C, et al (2000) Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 82:1254–1260

    Article  PubMed  CAS  Google Scholar 

  • Richardson PG, Sonneveld P, Schuster M, et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New Engl J Med 52:2487–2498

    Article  Google Scholar 

  • Richardson PG, Sonneveld P, Schuster M, et al (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood 110:3557–3560

    Article  PubMed  CAS  Google Scholar 

  • Salmon SE, Tesh D, Crowley J, et al (1990) Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 8:1575–1584

    PubMed  CAS  Google Scholar 

  • San Miguel J, Lahuerta JJ, Garcia-Sanz R, et al (2000) Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Haematol J 1:28–36

    CAS  Google Scholar 

  • Shustik C, Belch A, Robinson S, et al (2007) A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol 136:203–211

    Article  PubMed  CAS  Google Scholar 

  • Siegel DS, Desikan KR, Mehta J, et al (1999) Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 93:51–54

    PubMed  CAS  Google Scholar 

  • Sirohi B, Powles R, Traleaven J, et al (2000) The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 25:533–539

    Article  PubMed  CAS  Google Scholar 

  • Sirohi B, Powles R, Mehta J, et al (2001) The implication of compromised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single-center study of 251 previously untreated patients. Med Oncol 18:39–50

    Article  PubMed  CAS  Google Scholar 

  • Stewart AK, Vescio R, Schiller G, et al (2001) Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 19:3771–3779

    PubMed  CAS  Google Scholar 

  • Stewart AK, Bergsagel PL, Greipp P, et al (2007). A practical guide to defining high-risk myeloma for clinical trials, patients counseling and choice of therapy. Leukaemia 21:529–534

    Article  CAS  Google Scholar 

  • Susnerwala SS, Shanks JH, Banerjee SS, et al (1997) Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. Br J Cancer 75:921–927

    PubMed  CAS  Google Scholar 

  • Terpos E, Apperley JF, Samson D, et al (2003) Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant 31:163–170

    Article  PubMed  CAS  Google Scholar 

  • The International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749–757

    Article  Google Scholar 

  • Tsang RW, Gospodarowicz MK, Pintilie M, et al (2001) Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys 50:113–120

    PubMed  CAS  Google Scholar 

  • Walker R, Barlogie B, Haessler J, et al (2007) Magnetic resonance imaging in multiple myeloa: diagnostic and clinical implications. J Clin Oncol 25:1121–1128

    Article  PubMed  Google Scholar 

  • Weber DM, Chen C, Niesvizky R, et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New Engl J Med 357:2133–2142

    Article  PubMed  CAS  Google Scholar 

  • Wilder RB, Ha CS, Cox JD, et al (2002) Persistence of myeloma protein for more than 1 year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer 94:1532–1537

    Article  PubMed  CAS  Google Scholar 

  • Wu KL, Beverloo B, Lokhorst HM, et al (2007) Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol 136:615–623

    Article  PubMed  CAS  Google Scholar 

  • Zervas K, Verrou E, Teleioudis Z, et al (2006) Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134:620–623

    Article  PubMed  CAS  Google Scholar 

  • Zucchelli P, Pasquali S, Cagnoli L, Ferrari G (1988) Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 33:1175–1180

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology Oncology, National University Cancer Institute of Singapore, National University Health System, National University of Singapore, 5 Lower Kent Ridge Road, Singapore, 119074, Singapore

    Wee Joo Chng MD

  2. Department of Radiation Oncology, National University Cancer Institute of Singapore, National University Health System, National University of Singapore, 5 Lower Kent Ridge Road, Singapore, 119074, Singapore

    Jiade J. Lu MBA

Authors
  1. Wee Joo Chng MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiade J. Lu MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology National University Cancer Institute of Singapore National University Health System, National University of Singapore, 5 Lower Kent Ridge Road, Singapore, 119074, Singapore

    Jiade J. Lu MD, MBA (Associate Professor and Consultant and Distinguished Clinical Professor) (Associate Professor and Consultant and Distinguished Clinical Professor)

  2. Department of Radiation Oncology, Cancer Hospital of Fudan University, 270 Dong An Road, Shanghai, 200232, P.R. China

    Jiade J. Lu MD, MBA (Associate Professor and Consultant and Distinguished Clinical Professor) (Associate Professor and Consultant and Distinguished Clinical Professor)

  3. College of Medicine, Drexel University, Broad & Vine Sts., Mail Stop 200, Philadelphia, PA, 19102-1192, USA

    Luther W. Brady MD (Hylda Cohn/American Cancer Society Professor of Clinical Oncology, and Professor, Department of Radiation Oncology Distinguished University Professor) (Hylda Cohn/American Cancer Society Professor of Clinical Oncology, and Professor, Department of Radiation Oncology Distinguished University Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Chng, W.J., Lu, J.J. (2008). Multiple Myeloma and Plasmacytoma. In: Lu, J.J., Brady, L.W. (eds) Radiation Oncology. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-77385-6_29

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-77385-6_29

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-77384-9

  • Online ISBN: 978-3-540-77385-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation